| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 111 | 2025 | 1120 | 14.270 |
Why?
|
| Transplantation Tolerance | 38 | 2025 | 143 | 11.250 |
Why?
|
| B-Lymphocytes | 41 | 2025 | 701 | 8.170 |
Why?
|
| Isoantibodies | 33 | 2025 | 127 | 7.730 |
Why?
|
| Organ Transplantation | 26 | 2024 | 295 | 6.960 |
Why?
|
| Heart Transplantation | 61 | 2025 | 811 | 6.210 |
Why?
|
| Graft Survival | 53 | 2025 | 937 | 5.120 |
Why?
|
| Kidney Transplantation | 26 | 2025 | 870 | 4.310 |
Why?
|
| Immune Tolerance | 27 | 2025 | 375 | 4.090 |
Why?
|
| Immunosuppressive Agents | 53 | 2017 | 990 | 3.250 |
Why?
|
| T-Lymphocytes | 36 | 2024 | 1275 | 3.200 |
Why?
|
| Immunologic Memory | 14 | 2024 | 184 | 3.110 |
Why?
|
| Transplantation, Heterologous | 39 | 2024 | 371 | 3.040 |
Why?
|
| Isoxazoles | 41 | 2006 | 78 | 2.930 |
Why?
|
| CD4-Positive T-Lymphocytes | 16 | 2025 | 481 | 2.700 |
Why?
|
| CD40 Ligand | 13 | 2025 | 77 | 2.700 |
Why?
|
| Mice | 128 | 2025 | 12269 | 2.640 |
Why?
|
| Mice, Inbred BALB C | 42 | 2025 | 1101 | 2.500 |
Why?
|
| Skin Transplantation | 14 | 2024 | 191 | 2.480 |
Why?
|
| Transplantation, Homologous | 43 | 2025 | 1014 | 2.430 |
Why?
|
| Allografts | 18 | 2025 | 205 | 2.410 |
Why?
|
| Animals | 182 | 2025 | 28155 | 2.390 |
Why?
|
| Mice, Inbred C57BL | 54 | 2025 | 3435 | 2.350 |
Why?
|
| Lymphocyte Activation | 24 | 2017 | 797 | 2.010 |
Why?
|
| Isoantigens | 12 | 2024 | 72 | 1.970 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2024 | 660 | 1.840 |
Why?
|
| HLA Antigens | 9 | 2023 | 228 | 1.720 |
Why?
|
| Germinal Center | 5 | 2025 | 62 | 1.710 |
Why?
|
| Immunity, Humoral | 4 | 2018 | 74 | 1.580 |
Why?
|
| Islets of Langerhans Transplantation | 16 | 2012 | 247 | 1.570 |
Why?
|
| T-Lymphocytes, Regulatory | 10 | 2025 | 337 | 1.470 |
Why?
|
| Transplantation Immunology | 8 | 2019 | 83 | 1.410 |
Why?
|
| Immunoglobulin G | 12 | 2023 | 464 | 1.380 |
Why?
|
| CTLA-4 Antigen | 8 | 2016 | 144 | 1.380 |
Why?
|
| Tissue Donors | 13 | 2023 | 541 | 1.380 |
Why?
|
| Diabetes Mellitus, Experimental | 12 | 2013 | 201 | 1.350 |
Why?
|
| Antibodies, Monoclonal | 20 | 2023 | 1395 | 1.250 |
Why?
|
| Disaccharides | 11 | 2008 | 24 | 1.250 |
Why?
|
| Listeriosis | 6 | 2019 | 90 | 1.220 |
Why?
|
| Toll-Like Receptors | 6 | 2009 | 102 | 1.190 |
Why?
|
| Listeria monocytogenes | 5 | 2019 | 97 | 1.190 |
Why?
|
| Galactosyltransferases | 11 | 2014 | 42 | 1.160 |
Why?
|
| Abatacept | 9 | 2020 | 87 | 1.140 |
Why?
|
| Nanofibers | 7 | 2020 | 32 | 1.140 |
Why?
|
| Major Histocompatibility Complex | 5 | 2023 | 86 | 1.130 |
Why?
|
| Antigen-Presenting Cells | 7 | 2024 | 145 | 1.120 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2019 | 287 | 1.100 |
Why?
|
| Killer Cells, Natural | 13 | 2008 | 286 | 1.070 |
Why?
|
| Rats, Inbred Lew | 38 | 2008 | 214 | 1.060 |
Why?
|
| Humans | 117 | 2025 | 93511 | 1.050 |
Why?
|
| Interferon-gamma | 15 | 2016 | 460 | 1.040 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2025 | 171 | 1.020 |
Why?
|
| B-Lymphocytes, Regulatory | 3 | 2019 | 8 | 1.010 |
Why?
|
| Bacterial Infections | 4 | 2014 | 179 | 0.990 |
Why?
|
| Disease Models, Animal | 14 | 2024 | 2495 | 0.980 |
Why?
|
| Antibodies | 11 | 2022 | 348 | 0.970 |
Why?
|
| Mice, Transgenic | 17 | 2025 | 1587 | 0.950 |
Why?
|
| Rats | 54 | 2023 | 4072 | 0.950 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2023 | 149 | 0.950 |
Why?
|
| Insulin-Secreting Cells | 4 | 2013 | 441 | 0.920 |
Why?
|
| Spleen | 12 | 2020 | 374 | 0.880 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2018 | 36 | 0.840 |
Why?
|
| Primary Graft Dysfunction | 1 | 2024 | 44 | 0.830 |
Why?
|
| Immunoconjugates | 6 | 2016 | 129 | 0.830 |
Why?
|
| Phenanthrenes | 1 | 2023 | 4 | 0.820 |
Why?
|
| Staphylococcus aureus | 9 | 2022 | 284 | 0.810 |
Why?
|
| Diterpenes | 1 | 2023 | 24 | 0.810 |
Why?
|
| Mice, Knockout | 29 | 2019 | 2121 | 0.800 |
Why?
|
| Prodrugs | 1 | 2023 | 51 | 0.790 |
Why?
|
| Staphylococcal Infections | 5 | 2022 | 286 | 0.780 |
Why?
|
| Dendritic Cells | 4 | 2024 | 536 | 0.770 |
Why?
|
| Sugars | 1 | 2022 | 4 | 0.760 |
Why?
|
| Regeneration | 5 | 2014 | 159 | 0.750 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 277 | 0.730 |
Why?
|
| Antigens | 5 | 2022 | 224 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2012 | 589 | 0.720 |
Why?
|
| Antibody Formation | 14 | 2022 | 169 | 0.720 |
Why?
|
| Adaptive Immunity | 6 | 2020 | 179 | 0.710 |
Why?
|
| Female | 50 | 2024 | 48698 | 0.700 |
Why?
|
| Cyclosporine | 20 | 2000 | 241 | 0.700 |
Why?
|
| Signal Transduction | 13 | 2023 | 3502 | 0.680 |
Why?
|
| Lung Transplantation | 2 | 2024 | 367 | 0.670 |
Why?
|
| Interleukin-10 | 3 | 2017 | 163 | 0.670 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2021 | 11 | 0.670 |
Why?
|
| Inflammation | 8 | 2022 | 1050 | 0.670 |
Why?
|
| Killer Cells, Lymphokine-Activated | 10 | 1996 | 27 | 0.640 |
Why?
|
| Pancreas Transplantation | 6 | 2008 | 104 | 0.630 |
Why?
|
| Kidney | 9 | 2023 | 1111 | 0.630 |
Why?
|
| Fetus | 2 | 2021 | 236 | 0.630 |
Why?
|
| Autoimmunity | 3 | 2019 | 189 | 0.620 |
Why?
|
| Congresses as Topic | 1 | 2020 | 124 | 0.600 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2016 | 319 | 0.600 |
Why?
|
| Peptides | 9 | 2023 | 656 | 0.600 |
Why?
|
| Transplants | 3 | 2022 | 43 | 0.590 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 46 | 0.580 |
Why?
|
| Plasma Cells | 3 | 2017 | 84 | 0.580 |
Why?
|
| Complement Activation | 3 | 2008 | 84 | 0.580 |
Why?
|
| Mice, Inbred C3H | 12 | 2011 | 369 | 0.570 |
Why?
|
| Th1 Cells | 2 | 2014 | 167 | 0.570 |
Why?
|
| Th2 Cells | 2 | 2014 | 149 | 0.570 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2023 | 207 | 0.570 |
Why?
|
| Adjuvants, Immunologic | 6 | 2020 | 173 | 0.570 |
Why?
|
| Apoptosis | 5 | 2023 | 1721 | 0.560 |
Why?
|
| Pregnancy | 5 | 2024 | 3147 | 0.550 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2023 | 103 | 0.540 |
Why?
|
| Immunologic Techniques | 1 | 2017 | 25 | 0.540 |
Why?
|
| Receptors, IgG | 7 | 2008 | 68 | 0.540 |
Why?
|
| Lung | 5 | 2024 | 1366 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 715 | 0.530 |
Why?
|
| Male | 51 | 2025 | 44553 | 0.520 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2017 | 688 | 0.520 |
Why?
|
| Staphylococcal Skin Infections | 4 | 2022 | 25 | 0.520 |
Why?
|
| Interleukin-2 | 13 | 2022 | 244 | 0.520 |
Why?
|
| Cytokines | 9 | 2023 | 863 | 0.520 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2303 | 0.520 |
Why?
|
| Influenza Vaccines | 2 | 2018 | 168 | 0.500 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 1995 | 215 | 0.500 |
Why?
|
| Antigens, Differentiation | 7 | 2004 | 124 | 0.490 |
Why?
|
| Transplantation, Heterotopic | 11 | 2010 | 47 | 0.480 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 305 | 0.470 |
Why?
|
| Clonal Deletion | 3 | 2020 | 23 | 0.470 |
Why?
|
| Antigens, CD | 13 | 2018 | 476 | 0.450 |
Why?
|
| Models, Animal | 6 | 2024 | 282 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 939 | 0.450 |
Why?
|
| Monitoring, Immunologic | 2 | 2015 | 19 | 0.450 |
Why?
|
| Interleukin-6 | 3 | 2011 | 276 | 0.450 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 339 | 0.450 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1741 | 0.440 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2018 | 96 | 0.440 |
Why?
|
| Precision Medicine | 1 | 2019 | 456 | 0.440 |
Why?
|
| Luciferases | 4 | 2013 | 129 | 0.440 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 16 | 0.440 |
Why?
|
| Cell Lineage | 1 | 2016 | 321 | 0.440 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 429 | 0.440 |
Why?
|
| Laboratories | 1 | 2015 | 46 | 0.430 |
Why?
|
| Biomedical Research | 2 | 2020 | 438 | 0.430 |
Why?
|
| International Cooperation | 1 | 2015 | 133 | 0.430 |
Why?
|
| Islets of Langerhans | 7 | 2010 | 557 | 0.420 |
Why?
|
| Antiviral Agents | 5 | 2006 | 364 | 0.420 |
Why?
|
| CD3 Complex | 8 | 2012 | 135 | 0.420 |
Why?
|
| Lymph Nodes | 5 | 2024 | 548 | 0.410 |
Why?
|
| Immunization | 4 | 2024 | 154 | 0.410 |
Why?
|
| Antibodies, Bacterial | 4 | 2022 | 103 | 0.410 |
Why?
|
| Membrane Glycoproteins | 9 | 1998 | 444 | 0.390 |
Why?
|
| Uracil | 1 | 2013 | 54 | 0.390 |
Why?
|
| Societies, Medical | 4 | 2022 | 621 | 0.390 |
Why?
|
| Communicable Diseases | 1 | 2014 | 69 | 0.390 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 1998 | 302 | 0.390 |
Why?
|
| Antibodies, Heterophile | 5 | 2004 | 20 | 0.380 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 77 | 0.380 |
Why?
|
| Immunodominant Epitopes | 2 | 2025 | 23 | 0.380 |
Why?
|
| Up-Regulation | 4 | 2010 | 730 | 0.370 |
Why?
|
| Immunity, Innate | 4 | 2024 | 463 | 0.370 |
Why?
|
| Gender Identity | 2 | 2023 | 58 | 0.370 |
Why?
|
| Epitopes | 9 | 2017 | 254 | 0.360 |
Why?
|
| Piperidines | 1 | 2013 | 165 | 0.360 |
Why?
|
| Blood Glucose | 6 | 2016 | 867 | 0.360 |
Why?
|
| Bone Transplantation | 2 | 2003 | 79 | 0.360 |
Why?
|
| Receptors, Immunologic | 6 | 1996 | 140 | 0.350 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 98 | 0.350 |
Why?
|
| Cytomegalovirus | 3 | 2006 | 71 | 0.350 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 424 | 0.340 |
Why?
|
| CD4 Antigens | 6 | 2007 | 80 | 0.340 |
Why?
|
| Cytomegalovirus Infections | 4 | 2006 | 111 | 0.340 |
Why?
|
| Hydroxybutyrates | 4 | 1999 | 25 | 0.340 |
Why?
|
| Vaccines, Subunit | 4 | 2020 | 54 | 0.330 |
Why?
|
| Aniline Compounds | 4 | 1999 | 62 | 0.330 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 376 | 0.320 |
Why?
|
| Tacrolimus | 6 | 2013 | 372 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2020 | 9098 | 0.310 |
Why?
|
| Lymphocyte Depletion | 3 | 2010 | 101 | 0.310 |
Why?
|
| Liver | 8 | 2008 | 1210 | 0.310 |
Why?
|
| Bacteria | 1 | 2014 | 509 | 0.310 |
Why?
|
| Down-Regulation | 1 | 2010 | 524 | 0.290 |
Why?
|
| Immunoglobulin M | 8 | 2014 | 153 | 0.290 |
Why?
|
| Phenotype | 9 | 2016 | 2544 | 0.290 |
Why?
|
| Insulin | 2 | 2013 | 1185 | 0.290 |
Why?
|
| Uridine | 9 | 2006 | 54 | 0.280 |
Why?
|
| Graft vs Host Disease | 3 | 2009 | 365 | 0.280 |
Why?
|
| Time Factors | 15 | 2016 | 5410 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1997 | 104 | 0.280 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 6 | 1994 | 96 | 0.280 |
Why?
|
| Reperfusion Injury | 6 | 2024 | 148 | 0.280 |
Why?
|
| Biomarkers | 4 | 2023 | 1910 | 0.270 |
Why?
|
| Histocompatibility | 4 | 2023 | 66 | 0.270 |
Why?
|
| alpha-Galactosidase | 1 | 2007 | 5 | 0.270 |
Why?
|
| Cricetinae | 13 | 2000 | 532 | 0.270 |
Why?
|
| CD59 Antigens | 1 | 2007 | 17 | 0.270 |
Why?
|
| Biphenyl Compounds | 2 | 1998 | 60 | 0.270 |
Why?
|
| Ischemic Preconditioning | 2 | 2006 | 37 | 0.270 |
Why?
|
| Antigens, Surface | 1 | 2007 | 97 | 0.270 |
Why?
|
| Risk Factors | 5 | 2024 | 5898 | 0.260 |
Why?
|
| Mesocricetus | 12 | 2000 | 102 | 0.260 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 292 | 0.260 |
Why?
|
| Autoimmune Diseases | 3 | 1998 | 255 | 0.250 |
Why?
|
| Leukocyte Common Antigens | 3 | 1995 | 50 | 0.250 |
Why?
|
| NF-kappa B | 4 | 2023 | 408 | 0.250 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 192 | 0.250 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 140 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 3 | 2023 | 281 | 0.250 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 452 | 0.250 |
Why?
|
| Sex Factors | 4 | 2024 | 1105 | 0.240 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 25 | 0.240 |
Why?
|
| Cell Transplantation | 1 | 2006 | 46 | 0.240 |
Why?
|
| Consensus | 2 | 2020 | 368 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2465 | 0.230 |
Why?
|
| Swine | 10 | 2024 | 588 | 0.230 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 436 | 0.230 |
Why?
|
| Mice, Inbred Strains | 6 | 2015 | 280 | 0.230 |
Why?
|
| Cells, Cultured | 12 | 2007 | 2850 | 0.220 |
Why?
|
| Interferon Regulatory Factors | 2 | 2017 | 75 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 3 | 1994 | 174 | 0.220 |
Why?
|
| Cell Differentiation | 7 | 2018 | 1621 | 0.220 |
Why?
|
| Exotoxins | 2 | 2022 | 21 | 0.220 |
Why?
|
| Histocompatibility Testing | 3 | 2023 | 140 | 0.220 |
Why?
|
| Acute Disease | 6 | 2009 | 841 | 0.220 |
Why?
|
| Genes, Reporter | 4 | 2019 | 275 | 0.220 |
Why?
|
| Skin | 2 | 2019 | 578 | 0.220 |
Why?
|
| Transplantation | 2 | 2024 | 38 | 0.210 |
Why?
|
| Flow Cytometry | 6 | 2018 | 712 | 0.210 |
Why?
|
| Heterografts | 1 | 2024 | 116 | 0.200 |
Why?
|
| Epoxy Compounds | 1 | 2023 | 10 | 0.200 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 67 | 0.200 |
Why?
|
| Cross-Priming | 1 | 2023 | 54 | 0.200 |
Why?
|
| Cell Line | 12 | 2017 | 2464 | 0.200 |
Why?
|
| Transplantation Chimera | 3 | 2023 | 84 | 0.190 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2023 | 27 | 0.190 |
Why?
|
| Organ Specificity | 2 | 2022 | 279 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2016 | 35 | 0.190 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.190 |
Why?
|
| Antibody Specificity | 2 | 2020 | 126 | 0.190 |
Why?
|
| Microbiota | 3 | 2019 | 425 | 0.180 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2012 | 58 | 0.180 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 110 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 208 | 0.180 |
Why?
|
| Leukocidins | 1 | 2022 | 3 | 0.180 |
Why?
|
| Chronic Disease | 2 | 2024 | 960 | 0.180 |
Why?
|
| Streptozocin | 2 | 2013 | 56 | 0.180 |
Why?
|
| CD8 Antigens | 3 | 2000 | 82 | 0.180 |
Why?
|
| Liver Transplantation | 9 | 2002 | 1194 | 0.180 |
Why?
|
| Europe | 2 | 2020 | 337 | 0.170 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 4 | 1995 | 11 | 0.170 |
Why?
|
| Publications | 1 | 2021 | 32 | 0.170 |
Why?
|
| DNA-Binding Proteins | 5 | 2013 | 1234 | 0.170 |
Why?
|
| Honey | 1 | 2000 | 3 | 0.170 |
Why?
|
| Botulism | 1 | 2000 | 6 | 0.170 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 1985 | 0.170 |
Why?
|
| Interleukin-17 | 2 | 2014 | 109 | 0.170 |
Why?
|
| Anterior Eye Segment | 1 | 2020 | 9 | 0.170 |
Why?
|
| Tyrosine | 5 | 1999 | 131 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 85 | 0.170 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2020 | 6 | 0.170 |
Why?
|
| Trans-Activators | 3 | 2013 | 439 | 0.160 |
Why?
|
| H-2 Antigens | 3 | 2020 | 57 | 0.160 |
Why?
|
| Nitriles | 6 | 2005 | 154 | 0.160 |
Why?
|
| Growth Inhibitors | 3 | 2004 | 41 | 0.160 |
Why?
|
| Leadership | 1 | 2022 | 148 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 9 | 1999 | 1028 | 0.160 |
Why?
|
| Transcription Factors | 4 | 2022 | 1691 | 0.160 |
Why?
|
| Antigens, T-Independent | 1 | 2000 | 4 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 4 | 2014 | 309 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 131 | 0.160 |
Why?
|
| Bacterial Proteins | 2 | 2016 | 878 | 0.160 |
Why?
|
| North America | 1 | 2020 | 195 | 0.150 |
Why?
|
| Cell Division | 7 | 1999 | 693 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 555 | 0.150 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1799 | 0.150 |
Why?
|
| Phosphorylation | 7 | 1999 | 1133 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 962 | 0.150 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2755 | 0.150 |
Why?
|
| Macrophages | 4 | 1990 | 610 | 0.150 |
Why?
|
| Isoenzymes | 3 | 2013 | 272 | 0.150 |
Why?
|
| Cytidine Deaminase | 2 | 2016 | 25 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 255 | 0.150 |
Why?
|
| src-Family Kinases | 2 | 1997 | 70 | 0.150 |
Why?
|
| fas Receptor | 2 | 1999 | 73 | 0.150 |
Why?
|
| Granzymes | 1 | 2019 | 94 | 0.150 |
Why?
|
| Thymus Gland | 1 | 2020 | 196 | 0.150 |
Why?
|
| Glucose Tolerance Test | 3 | 2010 | 232 | 0.140 |
Why?
|
| Crotonates | 4 | 1999 | 12 | 0.140 |
Why?
|
| Toluidines | 4 | 1999 | 18 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 200 | 0.140 |
Why?
|
| Antigen Presentation | 1 | 2020 | 229 | 0.140 |
Why?
|
| Cell Adhesion | 6 | 1995 | 416 | 0.140 |
Why?
|
| Models, Immunological | 2 | 2017 | 84 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 829 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 666 | 0.140 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 240 | 0.140 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 44 | 0.140 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2018 | 56 | 0.130 |
Why?
|
| Drug Resistance | 3 | 1993 | 233 | 0.130 |
Why?
|
| Mice, SCID | 2 | 2010 | 271 | 0.130 |
Why?
|
| Mice, Inbred NOD | 6 | 2008 | 216 | 0.130 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 1997 | 10 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 1995 | 537 | 0.130 |
Why?
|
| Hybridomas | 3 | 2008 | 61 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 1997 | 111 | 0.130 |
Why?
|
| Clonal Anergy | 1 | 2017 | 32 | 0.130 |
Why?
|
| Mice, Inbred DBA | 3 | 2002 | 145 | 0.130 |
Why?
|
| Adoptive Transfer | 6 | 2016 | 172 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2021 | 277 | 0.130 |
Why?
|
| Central Tolerance | 1 | 2016 | 8 | 0.130 |
Why?
|
| Leukemia, Experimental | 1 | 1996 | 15 | 0.120 |
Why?
|
| Immune Sera | 5 | 2003 | 48 | 0.120 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.120 |
Why?
|
| Neutralization Tests | 2 | 2014 | 72 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2018 | 157 | 0.120 |
Why?
|
| Vaccines | 2 | 2014 | 84 | 0.120 |
Why?
|
| Kinetics | 5 | 2016 | 1492 | 0.120 |
Why?
|
| Integrases | 1 | 2016 | 66 | 0.120 |
Why?
|
| Cell Movement | 1 | 2020 | 809 | 0.120 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 67 | 0.120 |
Why?
|
| Polysaccharides | 2 | 2014 | 96 | 0.120 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 141 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2014 | 202 | 0.120 |
Why?
|
| Lymphotoxin-alpha | 2 | 1993 | 41 | 0.120 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2015 | 11 | 0.120 |
Why?
|
| 5'-Nucleotidase | 1 | 2015 | 14 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2012 | 470 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.110 |
Why?
|
| Drug Synergism | 3 | 2013 | 315 | 0.110 |
Why?
|
| Hemolysin Proteins | 2 | 2022 | 32 | 0.110 |
Why?
|
| Sirolimus | 2 | 2013 | 176 | 0.110 |
Why?
|
| Lymphocytes | 3 | 2008 | 454 | 0.110 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 135 | 0.110 |
Why?
|
| Plasmodium | 1 | 2014 | 11 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2015 | 22 | 0.110 |
Why?
|
| Pyrimidine Nucleotides | 3 | 1999 | 7 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2016 | 836 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2014 | 15 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 317 | 0.110 |
Why?
|
| Bacterial Toxins | 2 | 2022 | 112 | 0.110 |
Why?
|
| Prognosis | 2 | 2014 | 3910 | 0.110 |
Why?
|
| Gene Expression | 3 | 2013 | 1301 | 0.110 |
Why?
|
| Transfection | 4 | 1998 | 880 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2015 | 210 | 0.110 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 164 | 0.100 |
Why?
|
| Rabbits | 2 | 2013 | 618 | 0.100 |
Why?
|
| Antigen-Antibody Complex | 1 | 2014 | 88 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 1996 | 409 | 0.100 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2014 | 24 | 0.100 |
Why?
|
| Research Report | 1 | 2014 | 43 | 0.100 |
Why?
|
| CD2 Antigens | 4 | 1994 | 22 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 192 | 0.100 |
Why?
|
| Intestine, Small | 4 | 1998 | 310 | 0.100 |
Why?
|
| Protein Kinase C | 2 | 2013 | 261 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 1999 | 1914 | 0.100 |
Why?
|
| Antigens, CD20 | 2 | 2012 | 33 | 0.100 |
Why?
|
| Nanostructures | 1 | 2014 | 89 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 64 | 0.100 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.100 |
Why?
|
| Immunity, Cellular | 5 | 2008 | 183 | 0.100 |
Why?
|
| Drug Therapy, Combination | 6 | 1998 | 759 | 0.100 |
Why?
|
| Vaccines, Synthetic | 1 | 2013 | 56 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2013 | 122 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 212 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1713 | 0.090 |
Why?
|
| Adult | 9 | 2020 | 27918 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1053 | 0.090 |
Why?
|
| Complement C4b | 1 | 2012 | 33 | 0.090 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.090 |
Why?
|
| Malaria | 1 | 2012 | 26 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1518 | 0.090 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 3 | 1997 | 34 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 322 | 0.090 |
Why?
|
| Binding, Competitive | 3 | 1999 | 141 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2022 | 367 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2014 | 563 | 0.090 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 178 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2018 | 122 | 0.090 |
Why?
|
| Genotype | 1 | 2016 | 1866 | 0.090 |
Why?
|
| Group Processes | 2 | 2023 | 30 | 0.090 |
Why?
|
| Viral Proteins | 2 | 2006 | 248 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 113 | 0.090 |
Why?
|
| Species Specificity | 4 | 2000 | 684 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 281 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 355 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 4560 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2011 | 66 | 0.080 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.080 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 259 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 1995 | 76 | 0.080 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1990 | 12 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 102 | 0.080 |
Why?
|
| Middle Aged | 8 | 2020 | 27569 | 0.080 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 37 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 1723 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1992 | 156 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2011 | 93 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 165 | 0.080 |
Why?
|
| Pancreatic Diseases | 1 | 2010 | 58 | 0.080 |
Why?
|
| Cell Death | 3 | 2007 | 253 | 0.080 |
Why?
|
| Cell Separation | 3 | 2024 | 200 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 889 | 0.080 |
Why?
|
| CD28 Antigens | 2 | 2004 | 94 | 0.080 |
Why?
|
| CD58 Antigens | 3 | 1994 | 5 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2010 | 127 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 199 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 727 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 2 | 1999 | 62 | 0.070 |
Why?
|
| Ischemia | 2 | 2014 | 253 | 0.070 |
Why?
|
| Monocytes | 1 | 1990 | 215 | 0.070 |
Why?
|
| Obesity | 1 | 2016 | 1018 | 0.070 |
Why?
|
| Gene Knock-In Techniques | 1 | 2009 | 28 | 0.070 |
Why?
|
| Heart | 2 | 2016 | 522 | 0.070 |
Why?
|
| Microspheres | 1 | 1988 | 88 | 0.070 |
Why?
|
| Lipopolysaccharides | 5 | 2017 | 301 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 8 | 1999 | 1245 | 0.070 |
Why?
|
| Biopsy | 1 | 2012 | 1175 | 0.070 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 31 | 0.070 |
Why?
|
| Bystander Effect | 1 | 2008 | 14 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2008 | 28 | 0.070 |
Why?
|
| Proteomics | 2 | 2024 | 264 | 0.070 |
Why?
|
| Luminescence | 1 | 2008 | 20 | 0.070 |
Why?
|
| DNA, Viral | 2 | 1999 | 234 | 0.070 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2008 | 77 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2008 | 71 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2003 | 756 | 0.070 |
Why?
|
| Reference Values | 2 | 2006 | 608 | 0.070 |
Why?
|
| Ovalbumin | 2 | 2022 | 102 | 0.070 |
Why?
|
| Protein Structure, Secondary | 3 | 2014 | 337 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2005 | 68 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 155 | 0.070 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2008 | 59 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2013 | 824 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 86 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 1995 | 948 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 1999 | 244 | 0.060 |
Why?
|
| Ligands | 1 | 2008 | 476 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2014 | 2440 | 0.060 |
Why?
|
| Interferon Type I | 1 | 2008 | 164 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 2 | 2013 | 66 | 0.060 |
Why?
|
| Protein Binding | 3 | 2020 | 1534 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 28 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2001 | 784 | 0.060 |
Why?
|
| Receptors, Antigen | 1 | 1986 | 13 | 0.060 |
Why?
|
| Rats, Inbred ACI | 4 | 2001 | 24 | 0.060 |
Why?
|
| Rats, Inbred BN | 5 | 2005 | 37 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2715 | 0.060 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2012 | 0.060 |
Why?
|
| Type C Phospholipases | 2 | 1996 | 26 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2006 | 20 | 0.060 |
Why?
|
| Embolism | 1 | 2006 | 32 | 0.060 |
Why?
|
| Age Factors | 3 | 2014 | 1906 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 162 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 89 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 151 | 0.060 |
Why?
|
| Neoplasms | 3 | 2025 | 3169 | 0.060 |
Why?
|
| Carrageenan | 1 | 1985 | 9 | 0.060 |
Why?
|
| Organ Preservation | 2 | 2014 | 130 | 0.060 |
Why?
|
| Bone Marrow | 2 | 1998 | 409 | 0.060 |
Why?
|
| Portal Vein | 1 | 2006 | 119 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 1999 | 641 | 0.060 |
Why?
|
| Fasting | 2 | 1995 | 163 | 0.050 |
Why?
|
| Autoantigens | 2 | 2016 | 138 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 2910 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 767 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2006 | 181 | 0.050 |
Why?
|
| Infant | 2 | 2022 | 3220 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2025 | 75 | 0.050 |
Why?
|
| Tilapia | 1 | 2004 | 1 | 0.050 |
Why?
|
| Interleukin-4 | 2 | 2002 | 134 | 0.050 |
Why?
|
| Bias | 1 | 2024 | 137 | 0.050 |
Why?
|
| Immunity | 2 | 2022 | 153 | 0.050 |
Why?
|
| Young Adult | 4 | 2022 | 6930 | 0.050 |
Why?
|
| Sporozoites | 2 | 2014 | 3 | 0.050 |
Why?
|
| Metabolomics | 1 | 2024 | 98 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 183 | 0.050 |
Why?
|
| Antibodies, Protozoan | 2 | 2014 | 46 | 0.050 |
Why?
|
| Stem Cells | 1 | 2006 | 387 | 0.050 |
Why?
|
| Chimerism | 1 | 2023 | 38 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2003 | 47 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 304 | 0.050 |
Why?
|
| Cloning, Organism | 1 | 2003 | 19 | 0.050 |
Why?
|
| Myocardium | 2 | 2004 | 570 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2003 | 38 | 0.050 |
Why?
|
| Body Weight | 3 | 2016 | 449 | 0.050 |
Why?
|
| Germany | 1 | 2022 | 81 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2026 | 0.050 |
Why?
|
| Virus Replication | 2 | 2005 | 284 | 0.050 |
Why?
|
| beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2001 | 674 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1117 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2003 | 239 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2001 | 9 | 0.040 |
Why?
|
| Hemin | 1 | 2001 | 5 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 56 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 61 | 0.040 |
Why?
|
| Fas Ligand Protein | 2 | 1998 | 47 | 0.040 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 32 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2021 | 37 | 0.040 |
Why?
|
| Drug Combinations | 2 | 1998 | 200 | 0.040 |
Why?
|
| Scrapie | 1 | 2001 | 2 | 0.040 |
Why?
|
| Astrocytes | 1 | 2001 | 141 | 0.040 |
Why?
|
| Clostridium botulinum | 1 | 2000 | 2 | 0.040 |
Why?
|
| PrPSc Proteins | 1 | 2001 | 21 | 0.040 |
Why?
|
| Janus Kinase 3 | 2 | 1998 | 9 | 0.040 |
Why?
|
| Biolistics | 2 | 1998 | 3 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 3828 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2000 | 30 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 216 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2020 | 13 | 0.040 |
Why?
|
| Adolescent | 4 | 2022 | 9606 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 27 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 55 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 77 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2020 | 5 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 220 | 0.040 |
Why?
|
| Trisaccharides | 1 | 2000 | 12 | 0.040 |
Why?
|
| Bortezomib | 1 | 2020 | 82 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 82 | 0.040 |
Why?
|
| Mice, Congenic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1999 | 17 | 0.040 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1999 | 10 | 0.040 |
Why?
|
| Foscarnet | 1 | 1999 | 9 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2019 | 39 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 1999 | 45 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1999 | 22 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 94 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 52 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 83 | 0.040 |
Why?
|
| B7-1 Antigen | 2 | 2013 | 75 | 0.040 |
Why?
|
| Staphylococcus epidermidis | 1 | 2019 | 16 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 85 | 0.040 |
Why?
|
| Models, Biological | 2 | 1998 | 1768 | 0.040 |
Why?
|
| Pancreas | 1 | 2001 | 258 | 0.040 |
Why?
|
| Neuropeptides | 1 | 1999 | 114 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 198 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 20 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 399 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2001 | 212 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 174 | 0.040 |
Why?
|
| Caspase 1 | 1 | 1998 | 20 | 0.040 |
Why?
|
| Leukemia, T-Cell | 1 | 1998 | 17 | 0.040 |
Why?
|
| HT29 Cells | 1 | 1998 | 49 | 0.040 |
Why?
|
| Binding Sites | 2 | 2017 | 1133 | 0.040 |
Why?
|
| Transcriptome | 1 | 2024 | 762 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 65 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 66 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 740 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 391 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 1998 | 59 | 0.030 |
Why?
|
| Cell Survival | 2 | 2001 | 1004 | 0.030 |
Why?
|
| Stimulation, Chemical | 2 | 1996 | 57 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 88 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 115 | 0.030 |
Why?
|
| Cytidine Triphosphate | 1 | 1997 | 3 | 0.030 |
Why?
|
| Uridine Triphosphate | 1 | 1997 | 7 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 36 | 0.030 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.030 |
Why?
|
| Vaccination | 1 | 2020 | 304 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 86 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 15 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 350 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 1997 | 15 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 49 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 266 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.030 |
Why?
|
| Cell Membrane | 4 | 2000 | 664 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 126 | 0.030 |
Why?
|
| Child | 2 | 2022 | 7355 | 0.030 |
Why?
|
| Glioma | 1 | 1999 | 301 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1007 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 224 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2022 | 10164 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 617 | 0.030 |
Why?
|
| Aged | 4 | 2020 | 20430 | 0.030 |
Why?
|
| Rifabutin | 1 | 1996 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 1996 | 10 | 0.030 |
Why?
|
| Quinones | 1 | 1996 | 9 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 1996 | 15 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1996 | 31 | 0.030 |
Why?
|
| Benzoquinones | 1 | 1996 | 26 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1999 | 506 | 0.030 |
Why?
|
| Thymocytes | 1 | 2016 | 31 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 1948 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 18 | 0.030 |
Why?
|
| Clindamycin | 1 | 2016 | 15 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1546 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 113 | 0.030 |
Why?
|
| Leukemia | 2 | 2008 | 301 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 555 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 1996 | 36 | 0.030 |
Why?
|
| Verapamil | 2 | 1993 | 32 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 30 | 0.030 |
Why?
|
| PrPC Proteins | 1 | 1996 | 13 | 0.030 |
Why?
|
| Rhodamine 123 | 2 | 1993 | 8 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1931 | 0.030 |
Why?
|
| Rhodamines | 2 | 1993 | 20 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1996 | 44 | 0.030 |
Why?
|
| Genistein | 1 | 1995 | 16 | 0.030 |
Why?
|
| Isoflavones | 1 | 1995 | 13 | 0.030 |
Why?
|
| Prions | 1 | 1996 | 52 | 0.030 |
Why?
|
| Sulfhydryl Reagents | 1 | 1995 | 9 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 1995 | 13 | 0.030 |
Why?
|
| Vanadates | 1 | 1995 | 32 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1448 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 158 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1103 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 1995 | 14 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1995 | 22 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 210 | 0.030 |
Why?
|
| Anopheles | 1 | 2014 | 4 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1917 | 0.030 |
Why?
|
| Recurrence | 3 | 2008 | 1190 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 135 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 1994 | 18 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2014 | 55 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 3829 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2014 | 83 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 873 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 20 | 0.030 |
Why?
|
| Empyema | 1 | 1994 | 9 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 21 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 1996 | 245 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 137 | 0.030 |
Why?
|
| Alum Compounds | 1 | 2013 | 5 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 95 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 73 | 0.030 |
Why?
|
| Protein Kinase C-theta | 1 | 2013 | 16 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2013 | 42 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 120 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2014 | 145 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 73 | 0.020 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 16 | 0.020 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2013 | 15 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2013 | 42 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 192 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 78 | 0.020 |
Why?
|
| Polyenes | 1 | 1993 | 8 | 0.020 |
Why?
|
| Nitrophenols | 1 | 2013 | 12 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 691 | 0.020 |
Why?
|
| Tritium | 1 | 1993 | 116 | 0.020 |
Why?
|
| Propylamines | 1 | 1993 | 7 | 0.020 |
Why?
|
| Thymidine | 1 | 1993 | 59 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 48 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2013 | 46 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1077 | 0.020 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1992 | 11 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 91 | 0.020 |
Why?
|
| Rituximab | 1 | 2013 | 128 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 195 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1993 | 239 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 172 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 988 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 1991 | 69 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 1 | 1991 | 1 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1995 | 111 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 191 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1991 | 73 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 1990 | 10 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1990 | 16 | 0.020 |
Why?
|
| Lymphoma | 2 | 1990 | 247 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2019 | 2562 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1990 | 49 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 1176 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 39 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1990 | 41 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1992 | 174 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1995 | 422 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 729 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1991 | 175 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 38 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 388 | 0.020 |
Why?
|
| Killer Factors, Yeast | 1 | 1989 | 1 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1989 | 47 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 19 | 0.020 |
Why?
|
| Periodic Acid | 1 | 1988 | 4 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1988 | 45 | 0.020 |
Why?
|
| Trypsin | 1 | 1988 | 94 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1988 | 25 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2009 | 92 | 0.020 |
Why?
|
| Biological Assay | 1 | 1989 | 82 | 0.020 |
Why?
|
| Clone Cells | 1 | 1989 | 219 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 37 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 775 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 887 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 2220 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1998 | 160 | 0.020 |
Why?
|
| Rodentia | 1 | 2007 | 47 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 1995 | 1264 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1986 | 28 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1986 | 2 | 0.020 |
Why?
|
| Mycobacterium bovis | 1 | 1986 | 16 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1531 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 319 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 2 | 1997 | 38 | 0.010 |
Why?
|
| Rose Bengal | 1 | 1985 | 3 | 0.010 |
Why?
|
| Polyelectrolytes | 1 | 1985 | 5 | 0.010 |
Why?
|
| Colorimetry | 1 | 1985 | 8 | 0.010 |
Why?
|
| Endocytosis | 1 | 1986 | 184 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1985 | 163 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1985 | 46 | 0.010 |
Why?
|
| Alkynes | 1 | 2005 | 21 | 0.010 |
Why?
|
| Alleles | 1 | 2008 | 1139 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2004 | 37 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1991 | 1415 | 0.010 |
Why?
|
| Neutrophils | 1 | 1986 | 324 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 556 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 700 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 35 | 0.010 |
Why?
|
| Polymers | 1 | 1985 | 218 | 0.010 |
Why?
|
| Temperature | 1 | 1985 | 424 | 0.010 |
Why?
|
| Proteins | 1 | 1989 | 803 | 0.010 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2003 | 15 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 347 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 2002 | 3 | 0.010 |
Why?
|
| Leukosialin | 1 | 2002 | 16 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 217 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 31 | 0.010 |
Why?
|
| Pregnatrienes | 1 | 2001 | 14 | 0.010 |
Why?
|
| Phenanthrolines | 1 | 2001 | 8 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2001 | 25 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 33 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2001 | 113 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2001 | 52 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2002 | 53 | 0.010 |
Why?
|
| Free Radicals | 1 | 2001 | 71 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 71 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 242 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 85 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 145 | 0.010 |
Why?
|
| Endopeptidase K | 1 | 2001 | 12 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 293 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 264 | 0.010 |
Why?
|
| Vero Cells | 1 | 2001 | 99 | 0.010 |
Why?
|
| Anemia | 1 | 2002 | 134 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 291 | 0.010 |
Why?
|
| Antioxidants | 1 | 2001 | 231 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 608 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2000 | 12 | 0.010 |
Why?
|
| Neurons | 2 | 2001 | 1582 | 0.010 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 1999 | 2 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 1999 | 14 | 0.010 |
Why?
|
| Liver Circulation | 1 | 1999 | 28 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 84 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 7061 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 2017 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1999 | 89 | 0.010 |
Why?
|
| Thalamus | 1 | 2001 | 132 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 123 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 502 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1999 | 218 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2001 | 467 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1998 | 159 | 0.010 |
Why?
|
| STAT6 Transcription Factor | 1 | 1998 | 29 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 578 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1997 | 26 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 67 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 603 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1999 | 295 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1997 | 8 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 13 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 452 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1998 | 281 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1922 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1996 | 69 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 1996 | 117 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1996 | 111 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Marine Toxins | 1 | 1995 | 4 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1995 | 25 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Oxazoles | 1 | 1995 | 13 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1995 | 36 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 58 | 0.010 |
Why?
|
| Naphthalenes | 1 | 1995 | 40 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 383 | 0.010 |
Why?
|
| Bile | 1 | 1995 | 60 | 0.010 |
Why?
|
| Glycogen | 1 | 1995 | 59 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1996 | 517 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 300 | 0.010 |
Why?
|
| Duodenal Neoplasms | 1 | 1994 | 21 | 0.010 |
Why?
|
| Ileostomy | 1 | 1994 | 28 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1995 | 410 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1995 | 198 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 515 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1994 | 48 | 0.010 |
Why?
|
| Weight Gain | 1 | 1994 | 128 | 0.010 |
Why?
|
| Chloroquine | 1 | 1993 | 13 | 0.010 |
Why?
|
| Stearic Acids | 1 | 1993 | 11 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1993 | 54 | 0.010 |
Why?
|
| Perforin | 1 | 1993 | 56 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 579 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1995 | 411 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1995 | 914 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 572 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1992 | 18 | 0.010 |
Why?
|
| Actins | 1 | 1995 | 467 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1996 | 396 | 0.010 |
Why?
|
| Probability | 1 | 1993 | 355 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 210 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 19 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 884 | 0.010 |
Why?
|
| Biological Transport | 1 | 1991 | 404 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 894 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 373 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1990 | 43 | 0.000 |
Why?
|
| RNA | 1 | 1993 | 573 | 0.000 |
Why?
|
| Interferons | 1 | 1989 | 112 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1265 | 0.000 |
Why?
|